Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Purchases of Investments

Cash used to buy marketable securities and other investments.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments outflow grows to $0

Q1 FY2026 purchases of investments was $0, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was $0.

Context

  • Purchases of investments amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Purchases of investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Purchases of Investments vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Purchases of investments amounts to 0.0% of revenue for ARCT, versus a peer median of 111.5%.
ARCT Competitors
Purchases of Investments for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$871.01M USD+2.9%-15.7%1329.9%
NVAXNovavax, Inc.LTM Mar 2026$544.67M USD-42.1%—91.3%
ABUSArbutus Biopharma CorporationLTM Mar 2026$252.14M USD+67.2%—131.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$233.85M USD-43.9%-19.7%—
SLNSilence Therapeutics plcLTM Mar 2026$233.23M USD—+102.8%25310.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$185.33M USD-42.4%-9.8%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$7.92M USD-82.2%-72.9%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 USD——0.0%
VALNValneva SELTM Mar 2026€0 EUR——0.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026$0 USD———
PRQRProQR Therapeutics N.V.LTM Mar 2026€0 EUR——0.0%
Peer median (excluding ARCT) —-42.2%-15.7%111.5%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
Deferred Income Tax00000
Stock-Based Compensation28.92M30.61M34.65M37.99M25.41M
Change in Working Capital32.63M(12.56M)7.38M(20.81M)(39.2M)
Accounts Receivables(1.24M)603K(29.3M)28.09M(1.59M)
Inventory00000
Accounts Payables(769K)(3.11M)(2.24M)1.92M(2.96M)
Other Working Capital34.64M(10.05M)38.92M(50.81M)(34.65M)
Other Non-Cash Items5.9M3.06M(33.36M)471K2.28M
Operating Cash Flow(135.04M)31.99M(18.1M)(59.75M)(74.27M)
Capital Expenditures(3.41M)(7.73M)(2.9M)(648K)(230K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.41M)(7.73M)(2.9M)(648K)(230K)
Debt Repayment46.6M(5M)(27.36M)00
Common Stock Issued515K411K609K682K13.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities902K1.73M2.67M4.74M0
Financing Cash Flow48.02M(2.86M)(24.09M)5.42M13.38M
Effect of Forex Changes00000
Net Change in Cash(90.43M)21.41M(45.09M)(54.98M)(61.12M)
Free Cash Flow(138.45M)24.27M(21M)(60.4M)(74.27M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.